Consun Pharmaceutical Group (HKG:1681) First Half 2024 Results
Key Financial Results
- Revenue: CN¥1.27b (up 13% from 1H 2023).
- Net income: CN¥399.8m (up 15% from 1H 2023).
- Profit margin: 32% (in line with 1H 2023).
- EPS: CN¥0.50 (up from CN¥0.44 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Consun Pharmaceutical Group Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Pharmaceuticals industry in Hong Kong.
Performance of the Hong Kong Pharmaceuticals industry.
The company's shares are up 11% from a week ago.
Risk Analysis
Be aware that Consun Pharmaceutical Group is showing 2 warning signs in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.